nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—UGT1A1—Estradiol—osteoporosis	0.0571	0.108	CbGbCtD
Regorafenib—ABCG2—Conjugated Estrogens—osteoporosis	0.0358	0.0676	CbGbCtD
Regorafenib—CYP2B6—Raloxifene—osteoporosis	0.0355	0.067	CbGbCtD
Regorafenib—CYP2B6—Ethinyl Estradiol—osteoporosis	0.0343	0.0647	CbGbCtD
Regorafenib—ABCG2—Estradiol—osteoporosis	0.0314	0.0593	CbGbCtD
Regorafenib—CYP2C9—Estropipate—osteoporosis	0.0281	0.0531	CbGbCtD
Regorafenib—CYP2B6—Cholecalciferol—osteoporosis	0.0274	0.0518	CbGbCtD
Regorafenib—CYP2C8—Raloxifene—osteoporosis	0.0269	0.0508	CbGbCtD
Regorafenib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.026	0.049	CbGbCtD
Regorafenib—CYP2C8—Cholecalciferol—osteoporosis	0.0208	0.0392	CbGbCtD
Regorafenib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0176	0.0332	CbGbCtD
Regorafenib—CYP2C19—Cholecalciferol—osteoporosis	0.0174	0.0329	CbGbCtD
Regorafenib—CYP2C8—Estradiol—osteoporosis	0.0167	0.0316	CbGbCtD
Regorafenib—CYP3A4—Estropipate—osteoporosis	0.0163	0.0309	CbGbCtD
Regorafenib—CYP3A4—Calcitriol—osteoporosis	0.0163	0.0309	CbGbCtD
Regorafenib—CYP2C9—Cholecalciferol—osteoporosis	0.0145	0.0273	CbGbCtD
Regorafenib—CYP2C19—Estradiol—osteoporosis	0.014	0.0265	CbGbCtD
Regorafenib—CYP3A4—Ergocalciferol—osteoporosis	0.0131	0.0247	CbGbCtD
Regorafenib—ABCB1—Conjugated Estrogens—osteoporosis	0.0129	0.0244	CbGbCtD
Regorafenib—CYP2C9—Estradiol—osteoporosis	0.0117	0.022	CbGbCtD
Regorafenib—ABCB1—Estradiol—osteoporosis	0.0113	0.0214	CbGbCtD
Regorafenib—CYP3A4—Raloxifene—osteoporosis	0.0109	0.0206	CbGbCtD
Regorafenib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0105	0.0199	CbGbCtD
Regorafenib—CYP3A4—Cholecalciferol—osteoporosis	0.00842	0.0159	CbGbCtD
Regorafenib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00773	0.0146	CbGbCtD
Regorafenib—CYP3A4—Estradiol—osteoporosis	0.00679	0.0128	CbGbCtD
Regorafenib—RET—parathyroid gland—osteoporosis	0.00651	0.194	CbGeAlD
Regorafenib—FGFR2—skull—osteoporosis	0.00633	0.189	CbGeAlD
Regorafenib—DDR2—uterus—osteoporosis	0.00206	0.0615	CbGeAlD
Regorafenib—FGFR2—Estradiol—Estropipate—osteoporosis	0.00166	0.368	CbGdCrCtD
Regorafenib—BRAF—uterus—osteoporosis	0.00146	0.0435	CbGeAlD
Regorafenib—EPHX2—uterus—osteoporosis	0.00139	0.0415	CbGeAlD
Regorafenib—FGFR2—Estradiol—Conjugated Estrogens—osteoporosis	0.00126	0.279	CbGdCrCtD
Regorafenib—FGFR1—uterus—osteoporosis	0.00124	0.037	CbGeAlD
Regorafenib—BRAF—bone marrow—osteoporosis	0.00124	0.0369	CbGeAlD
Regorafenib—FLT4—bone marrow—osteoporosis	0.00107	0.0318	CbGeAlD
Regorafenib—FGFR2—Estradiol—Ethinyl Estradiol—osteoporosis	0.00105	0.234	CbGdCrCtD
Regorafenib—FGFR2—uterus—osteoporosis	0.00105	0.0314	CbGeAlD
Regorafenib—TEK—uterus—osteoporosis	0.00101	0.0301	CbGeAlD
Regorafenib—FLT1—uterus—osteoporosis	0.000976	0.0291	CbGeAlD
Regorafenib—RAF1—uterus—osteoporosis	0.000971	0.029	CbGeAlD
Regorafenib—PDGFRA—uterus—osteoporosis	0.000915	0.0273	CbGeAlD
Regorafenib—KDR—uterus—osteoporosis	0.000825	0.0246	CbGeAlD
Regorafenib—RAF1—bone marrow—osteoporosis	0.000824	0.0246	CbGeAlD
Regorafenib—KIT—uterus—osteoporosis	0.000731	0.0218	CbGeAlD
Regorafenib—PDGFRB—uterus—osteoporosis	0.000714	0.0213	CbGeAlD
Regorafenib—KDR—bone marrow—osteoporosis	0.000701	0.0209	CbGeAlD
Regorafenib—ABL1—uterus—osteoporosis	0.000637	0.019	CbGeAlD
Regorafenib—KIT—bone marrow—osteoporosis	0.000621	0.0185	CbGeAlD
Regorafenib—PDGFRB—bone marrow—osteoporosis	0.000606	0.0181	CbGeAlD
Regorafenib—ABL1—bone marrow—osteoporosis	0.00054	0.0161	CbGeAlD
Regorafenib—ABL1—Levorphanol—Estradiol—osteoporosis	0.000538	0.119	CbGdCrCtD
Regorafenib—Angiopathy—Risedronate—osteoporosis	0.00043	0.00216	CcSEcCtD
Regorafenib—Alopecia—Ethinyl Estradiol—osteoporosis	0.000429	0.00215	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.000427	0.00214	CcSEcCtD
Regorafenib—Mediastinal disorder—Risedronate—osteoporosis	0.000427	0.00214	CcSEcCtD
Regorafenib—Infection—Estropipate—osteoporosis	0.000423	0.00212	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.000423	0.00212	CcSEcCtD
Regorafenib—Malnutrition—Ethinyl Estradiol—osteoporosis	0.000423	0.00212	CcSEcCtD
Regorafenib—Hypertension—Calcitriol—osteoporosis	0.000423	0.00212	CcSEcCtD
Regorafenib—Dry skin—Estradiol—osteoporosis	0.00042	0.00211	CcSEcCtD
Regorafenib—Cardiac disorder—Pamidronate—osteoporosis	0.000418	0.0021	CcSEcCtD
Regorafenib—Nervous system disorder—Estropipate—osteoporosis	0.000417	0.00209	CcSEcCtD
Regorafenib—Hepatobiliary disease—Conjugated Estrogens—osteoporosis	0.000417	0.00209	CcSEcCtD
Regorafenib—Infection—Alendronate—osteoporosis	0.000417	0.00209	CcSEcCtD
Regorafenib—Dry mouth—Ibandronate—osteoporosis	0.000416	0.00209	CcSEcCtD
Regorafenib—Skin disorder—Estropipate—osteoporosis	0.000413	0.00207	CcSEcCtD
Regorafenib—Malnutrition—Risedronate—osteoporosis	0.000412	0.00207	CcSEcCtD
Regorafenib—Infection—Raloxifene—osteoporosis	0.00041	0.00206	CcSEcCtD
Regorafenib—Angiopathy—Pamidronate—osteoporosis	0.000408	0.00205	CcSEcCtD
Regorafenib—Dry mouth—Calcitriol—osteoporosis	0.000408	0.00205	CcSEcCtD
Regorafenib—Urinary tract disorder—Zoledronate—osteoporosis	0.000406	0.00204	CcSEcCtD
Regorafenib—Mediastinal disorder—Pamidronate—osteoporosis	0.000406	0.00204	CcSEcCtD
Regorafenib—Infection—Ibandronate—osteoporosis	0.000406	0.00203	CcSEcCtD
Regorafenib—Nervous system disorder—Raloxifene—osteoporosis	0.000404	0.00203	CcSEcCtD
Regorafenib—Connective tissue disorder—Zoledronate—osteoporosis	0.000404	0.00203	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Estradiol—osteoporosis	0.000404	0.00203	CcSEcCtD
Regorafenib—Thrombocytopenia—Raloxifene—osteoporosis	0.000404	0.00203	CcSEcCtD
Regorafenib—Urethral disorder—Zoledronate—osteoporosis	0.000403	0.00202	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etidronic acid—osteoporosis	0.000402	0.00202	CcSEcCtD
Regorafenib—ABCG2—uterus—osteoporosis	0.000402	0.012	CbGeAlD
Regorafenib—Skin disorder—Raloxifene—osteoporosis	0.000401	0.00201	CcSEcCtD
Regorafenib—Nervous system disorder—Ibandronate—osteoporosis	0.0004	0.00201	CcSEcCtD
Regorafenib—Alopecia—Pamidronate—osteoporosis	0.000398	0.002	CcSEcCtD
Regorafenib—Skin disorder—Ibandronate—osteoporosis	0.000397	0.00199	CcSEcCtD
Regorafenib—Nausea—Ergocalciferol—osteoporosis	0.000393	0.00197	CcSEcCtD
Regorafenib—Malnutrition—Pamidronate—osteoporosis	0.000392	0.00197	CcSEcCtD
Regorafenib—Abdominal pain—Etidronic acid—osteoporosis	0.000389	0.00195	CcSEcCtD
Regorafenib—Skin disorder—Calcitriol—osteoporosis	0.000388	0.00195	CcSEcCtD
Regorafenib—Cardiac disorder—Zoledronate—osteoporosis	0.000382	0.00191	CcSEcCtD
Regorafenib—Anaemia—Risedronate—osteoporosis	0.000381	0.00191	CcSEcCtD
Regorafenib—Erythema multiforme—Conjugated Estrogens—osteoporosis	0.000374	0.00188	CcSEcCtD
Regorafenib—Angiopathy—Zoledronate—osteoporosis	0.000373	0.00187	CcSEcCtD
Regorafenib—Mediastinal disorder—Zoledronate—osteoporosis	0.000371	0.00186	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Estropipate—osteoporosis	0.000368	0.00184	CcSEcCtD
Regorafenib—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000367	0.00184	CcSEcCtD
Regorafenib—Fatigue—Estropipate—osteoporosis	0.000367	0.00184	CcSEcCtD
Regorafenib—Pain—Estropipate—osteoporosis	0.000364	0.00183	CcSEcCtD
Regorafenib—Alopecia—Zoledronate—osteoporosis	0.000363	0.00182	CcSEcCtD
Regorafenib—Anaemia—Pamidronate—osteoporosis	0.000362	0.00182	CcSEcCtD
Regorafenib—Angiopathy—Conjugated Estrogens—osteoporosis	0.000359	0.0018	CcSEcCtD
Regorafenib—Pain—Alendronate—osteoporosis	0.000359	0.0018	CcSEcCtD
Regorafenib—Weight decreased—Estradiol—osteoporosis	0.000358	0.0018	CcSEcCtD
Regorafenib—Malnutrition—Zoledronate—osteoporosis	0.000358	0.0018	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000357	0.00179	CcSEcCtD
Regorafenib—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000357	0.00179	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000356	0.00179	CcSEcCtD
Regorafenib—Hypertension—Risedronate—osteoporosis	0.000356	0.00179	CcSEcCtD
Regorafenib—Decreased appetite—Ibandronate—osteoporosis	0.000355	0.00178	CcSEcCtD
Regorafenib—Infestation NOS—Estradiol—osteoporosis	0.000353	0.00177	CcSEcCtD
Regorafenib—Infestation—Estradiol—osteoporosis	0.000353	0.00177	CcSEcCtD
Regorafenib—Pain—Raloxifene—osteoporosis	0.000353	0.00177	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000352	0.00177	CcSEcCtD
Regorafenib—Fatigue—Ibandronate—osteoporosis	0.000352	0.00177	CcSEcCtD
Regorafenib—Leukopenia—Pamidronate—osteoporosis	0.000351	0.00176	CcSEcCtD
Regorafenib—Alopecia—Conjugated Estrogens—osteoporosis	0.00035	0.00176	CcSEcCtD
Regorafenib—Pain—Ibandronate—osteoporosis	0.000349	0.00175	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000349	0.00175	CcSEcCtD
Regorafenib—Gastrointestinal pain—Estropipate—osteoporosis	0.000348	0.00175	CcSEcCtD
Regorafenib—Acute coronary syndrome—Estradiol—osteoporosis	0.000348	0.00175	CcSEcCtD
Regorafenib—Decreased appetite—Calcitriol—osteoporosis	0.000347	0.00174	CcSEcCtD
Regorafenib—Myocardial infarction—Estradiol—osteoporosis	0.000346	0.00174	CcSEcCtD
Regorafenib—Malnutrition—Conjugated Estrogens—osteoporosis	0.000345	0.00173	CcSEcCtD
Regorafenib—Dry mouth—Risedronate—osteoporosis	0.000343	0.00172	CcSEcCtD
Regorafenib—Gastrointestinal pain—Alendronate—osteoporosis	0.000343	0.00172	CcSEcCtD
Regorafenib—Infection—Ethinyl Estradiol—osteoporosis	0.000343	0.00172	CcSEcCtD
Regorafenib—Pain—Calcitriol—osteoporosis	0.000342	0.00171	CcSEcCtD
Regorafenib—ABCG2—bone marrow—osteoporosis	0.000341	0.0102	CbGeAlD
Regorafenib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000338	0.0017	CcSEcCtD
Regorafenib—Hypertension—Pamidronate—osteoporosis	0.000338	0.0017	CcSEcCtD
Regorafenib—Gastrointestinal pain—Raloxifene—osteoporosis	0.000337	0.00169	CcSEcCtD
Regorafenib—Diarrhoea—Etidronic acid—osteoporosis	0.000337	0.00169	CcSEcCtD
Regorafenib—Abdominal pain—Estropipate—osteoporosis	0.000337	0.00169	CcSEcCtD
Regorafenib—Body temperature increased—Estropipate—osteoporosis	0.000337	0.00169	CcSEcCtD
Regorafenib—Tremor—Zoledronate—osteoporosis	0.000335	0.00168	CcSEcCtD
Regorafenib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000335	0.00168	CcSEcCtD
Regorafenib—Infection—Risedronate—osteoporosis	0.000334	0.00168	CcSEcCtD
Regorafenib—Hepatobiliary disease—Estradiol—osteoporosis	0.000334	0.00167	CcSEcCtD
Regorafenib—Gastrointestinal pain—Ibandronate—osteoporosis	0.000334	0.00167	CcSEcCtD
Regorafenib—Abdominal pain—Alendronate—osteoporosis	0.000331	0.00166	CcSEcCtD
Regorafenib—Body temperature increased—Alendronate—osteoporosis	0.000331	0.00166	CcSEcCtD
Regorafenib—Anaemia—Zoledronate—osteoporosis	0.000331	0.00166	CcSEcCtD
Regorafenib—Nervous system disorder—Risedronate—osteoporosis	0.00033	0.00166	CcSEcCtD
Regorafenib—Skin disorder—Risedronate—osteoporosis	0.000327	0.00164	CcSEcCtD
Regorafenib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000327	0.00164	CcSEcCtD
Regorafenib—Body temperature increased—Raloxifene—osteoporosis	0.000326	0.00164	CcSEcCtD
Regorafenib—Abdominal pain—Raloxifene—osteoporosis	0.000326	0.00164	CcSEcCtD
Regorafenib—Body temperature increased—Ibandronate—osteoporosis	0.000323	0.00162	CcSEcCtD
Regorafenib—Abdominal pain—Ibandronate—osteoporosis	0.000323	0.00162	CcSEcCtD
Regorafenib—Leukopenia—Zoledronate—osteoporosis	0.00032	0.00161	CcSEcCtD
Regorafenib—Haemoglobin—Estradiol—osteoporosis	0.000318	0.0016	CcSEcCtD
Regorafenib—Infection—Pamidronate—osteoporosis	0.000318	0.00159	CcSEcCtD
Regorafenib—Haemorrhage—Estradiol—osteoporosis	0.000317	0.00159	CcSEcCtD
Regorafenib—Body temperature increased—Calcitriol—osteoporosis	0.000316	0.00158	CcSEcCtD
Regorafenib—Abdominal pain—Calcitriol—osteoporosis	0.000316	0.00158	CcSEcCtD
Regorafenib—Nervous system disorder—Pamidronate—osteoporosis	0.000314	0.00157	CcSEcCtD
Regorafenib—Thrombocytopenia—Pamidronate—osteoporosis	0.000313	0.00157	CcSEcCtD
Regorafenib—Urinary tract disorder—Estradiol—osteoporosis	0.000313	0.00157	CcSEcCtD
Regorafenib—Vomiting—Etidronic acid—osteoporosis	0.000313	0.00157	CcSEcCtD
Regorafenib—Connective tissue disorder—Estradiol—osteoporosis	0.000311	0.00156	CcSEcCtD
Regorafenib—Urethral disorder—Estradiol—osteoporosis	0.000311	0.00156	CcSEcCtD
Regorafenib—Rash—Etidronic acid—osteoporosis	0.00031	0.00156	CcSEcCtD
Regorafenib—Dermatitis—Etidronic acid—osteoporosis	0.00031	0.00156	CcSEcCtD
Regorafenib—Hypertension—Zoledronate—osteoporosis	0.000309	0.00155	CcSEcCtD
Regorafenib—Headache—Etidronic acid—osteoporosis	0.000308	0.00155	CcSEcCtD
Regorafenib—Asthenia—Estropipate—osteoporosis	0.000305	0.00153	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000303	0.00152	CcSEcCtD
Regorafenib—Asthenia—Alendronate—osteoporosis	0.000301	0.00151	CcSEcCtD
Regorafenib—Erythema multiforme—Estradiol—osteoporosis	0.0003	0.0015	CcSEcCtD
Regorafenib—Dry mouth—Zoledronate—osteoporosis	0.000298	0.0015	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000298	0.00149	CcSEcCtD
Regorafenib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000297	0.00149	CcSEcCtD
Regorafenib—Cardiac disorder—Estradiol—osteoporosis	0.000294	0.00148	CcSEcCtD
Regorafenib—Asthenia—Ibandronate—osteoporosis	0.000293	0.00147	CcSEcCtD
Regorafenib—Nausea—Etidronic acid—osteoporosis	0.000292	0.00147	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000291	0.00146	CcSEcCtD
Regorafenib—Diarrhoea—Estropipate—osteoporosis	0.000291	0.00146	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Risedronate—osteoporosis	0.00029	0.00146	CcSEcCtD
Regorafenib—Infection—Zoledronate—osteoporosis	0.00029	0.00146	CcSEcCtD
Regorafenib—Fatigue—Risedronate—osteoporosis	0.00029	0.00146	CcSEcCtD
Regorafenib—Pain—Risedronate—osteoporosis	0.000288	0.00144	CcSEcCtD
Regorafenib—Angiopathy—Estradiol—osteoporosis	0.000287	0.00144	CcSEcCtD
Regorafenib—Diarrhoea—Alendronate—osteoporosis	0.000287	0.00144	CcSEcCtD
Regorafenib—Asthenia—Calcitriol—osteoporosis	0.000287	0.00144	CcSEcCtD
Regorafenib—Nervous system disorder—Zoledronate—osteoporosis	0.000286	0.00144	CcSEcCtD
Regorafenib—Thrombocytopenia—Zoledronate—osteoporosis	0.000286	0.00144	CcSEcCtD
Regorafenib—Mediastinal disorder—Estradiol—osteoporosis	0.000286	0.00143	CcSEcCtD
Regorafenib—Skin disorder—Zoledronate—osteoporosis	0.000284	0.00142	CcSEcCtD
Regorafenib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000282	0.00142	CcSEcCtD
Regorafenib—Diarrhoea—Raloxifene—osteoporosis	0.000282	0.00142	CcSEcCtD
Regorafenib—Alopecia—Estradiol—osteoporosis	0.00028	0.0014	CcSEcCtD
Regorafenib—Infection—Conjugated Estrogens—osteoporosis	0.000279	0.0014	CcSEcCtD
Regorafenib—Diarrhoea—Ibandronate—osteoporosis	0.000279	0.0014	CcSEcCtD
Regorafenib—Decreased appetite—Pamidronate—osteoporosis	0.000278	0.00139	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000276	0.00139	CcSEcCtD
Regorafenib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000276	0.00138	CcSEcCtD
Regorafenib—Malnutrition—Estradiol—osteoporosis	0.000276	0.00138	CcSEcCtD
Regorafenib—Fatigue—Pamidronate—osteoporosis	0.000276	0.00138	CcSEcCtD
Regorafenib—Gastrointestinal pain—Risedronate—osteoporosis	0.000275	0.00138	CcSEcCtD
Regorafenib—Pain—Pamidronate—osteoporosis	0.000273	0.00137	CcSEcCtD
Regorafenib—Diarrhoea—Calcitriol—osteoporosis	0.000273	0.00137	CcSEcCtD
Regorafenib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000273	0.00137	CcSEcCtD
Regorafenib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000273	0.00137	CcSEcCtD
Regorafenib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000273	0.00137	CcSEcCtD
Regorafenib—Vomiting—Estropipate—osteoporosis	0.000271	0.00136	CcSEcCtD
Regorafenib—Rash—Estropipate—osteoporosis	0.000268	0.00135	CcSEcCtD
Regorafenib—Dermatitis—Estropipate—osteoporosis	0.000268	0.00135	CcSEcCtD
Regorafenib—Headache—Estropipate—osteoporosis	0.000267	0.00134	CcSEcCtD
Regorafenib—Vomiting—Alendronate—osteoporosis	0.000267	0.00134	CcSEcCtD
Regorafenib—Body temperature increased—Risedronate—osteoporosis	0.000266	0.00133	CcSEcCtD
Regorafenib—Abdominal pain—Risedronate—osteoporosis	0.000266	0.00133	CcSEcCtD
Regorafenib—Rash—Alendronate—osteoporosis	0.000264	0.00133	CcSEcCtD
Regorafenib—Dermatitis—Alendronate—osteoporosis	0.000264	0.00133	CcSEcCtD
Regorafenib—Headache—Alendronate—osteoporosis	0.000263	0.00132	CcSEcCtD
Regorafenib—Vomiting—Raloxifene—osteoporosis	0.000262	0.00132	CcSEcCtD
Regorafenib—Gastrointestinal pain—Pamidronate—osteoporosis	0.000262	0.00131	CcSEcCtD
Regorafenib—Rash—Raloxifene—osteoporosis	0.00026	0.0013	CcSEcCtD
Regorafenib—Dermatitis—Raloxifene—osteoporosis	0.00026	0.0013	CcSEcCtD
Regorafenib—Vomiting—Ibandronate—osteoporosis	0.00026	0.0013	CcSEcCtD
Regorafenib—Tremor—Estradiol—osteoporosis	0.000258	0.0013	CcSEcCtD
Regorafenib—Headache—Raloxifene—osteoporosis	0.000258	0.0013	CcSEcCtD
Regorafenib—Rash—Ibandronate—osteoporosis	0.000257	0.00129	CcSEcCtD
Regorafenib—Dermatitis—Ibandronate—osteoporosis	0.000257	0.00129	CcSEcCtD
Regorafenib—Headache—Ibandronate—osteoporosis	0.000256	0.00128	CcSEcCtD
Regorafenib—Vomiting—Calcitriol—osteoporosis	0.000254	0.00127	CcSEcCtD
Regorafenib—Decreased appetite—Zoledronate—osteoporosis	0.000254	0.00127	CcSEcCtD
Regorafenib—Nausea—Estropipate—osteoporosis	0.000253	0.00127	CcSEcCtD
Regorafenib—Body temperature increased—Pamidronate—osteoporosis	0.000253	0.00127	CcSEcCtD
Regorafenib—Abdominal pain—Pamidronate—osteoporosis	0.000253	0.00127	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000252	0.00127	CcSEcCtD
Regorafenib—Rash—Calcitriol—osteoporosis	0.000252	0.00126	CcSEcCtD
Regorafenib—Fatigue—Zoledronate—osteoporosis	0.000252	0.00126	CcSEcCtD
Regorafenib—Dermatitis—Calcitriol—osteoporosis	0.000252	0.00126	CcSEcCtD
Regorafenib—Headache—Calcitriol—osteoporosis	0.00025	0.00126	CcSEcCtD
Regorafenib—Pain—Zoledronate—osteoporosis	0.00025	0.00125	CcSEcCtD
Regorafenib—Nausea—Alendronate—osteoporosis	0.000249	0.00125	CcSEcCtD
Regorafenib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000248	0.00124	CcSEcCtD
Regorafenib—Nausea—Raloxifene—osteoporosis	0.000245	0.00123	CcSEcCtD
Regorafenib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000245	0.00123	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000243	0.00122	CcSEcCtD
Regorafenib—Fatigue—Conjugated Estrogens—osteoporosis	0.000243	0.00122	CcSEcCtD
Regorafenib—Nausea—Ibandronate—osteoporosis	0.000242	0.00122	CcSEcCtD
Regorafenib—Asthenia—Risedronate—osteoporosis	0.000241	0.00121	CcSEcCtD
Regorafenib—Pain—Conjugated Estrogens—osteoporosis	0.000241	0.00121	CcSEcCtD
Regorafenib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000239	0.0012	CcSEcCtD
Regorafenib—Hypertension—Estradiol—osteoporosis	0.000238	0.00119	CcSEcCtD
Regorafenib—Nausea—Calcitriol—osteoporosis	0.000237	0.00119	CcSEcCtD
Regorafenib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000236	0.00118	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000233	0.00117	CcSEcCtD
Regorafenib—Abdominal pain—Zoledronate—osteoporosis	0.000231	0.00116	CcSEcCtD
Regorafenib—Body temperature increased—Zoledronate—osteoporosis	0.000231	0.00116	CcSEcCtD
Regorafenib—Diarrhoea—Risedronate—osteoporosis	0.00023	0.00115	CcSEcCtD
Regorafenib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00023	0.00115	CcSEcCtD
Regorafenib—Dry mouth—Estradiol—osteoporosis	0.00023	0.00115	CcSEcCtD
Regorafenib—Asthenia—Pamidronate—osteoporosis	0.000229	0.00115	CcSEcCtD
Regorafenib—Infection—Estradiol—osteoporosis	0.000224	0.00112	CcSEcCtD
Regorafenib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000222	0.00112	CcSEcCtD
Regorafenib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000222	0.00112	CcSEcCtD
Regorafenib—Nervous system disorder—Estradiol—osteoporosis	0.000221	0.00111	CcSEcCtD
Regorafenib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000219	0.0011	CcSEcCtD
Regorafenib—Diarrhoea—Pamidronate—osteoporosis	0.000219	0.0011	CcSEcCtD
Regorafenib—Skin disorder—Estradiol—osteoporosis	0.000219	0.0011	CcSEcCtD
Regorafenib—Rash—Ethinyl Estradiol—osteoporosis	0.000218	0.00109	CcSEcCtD
Regorafenib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000217	0.00109	CcSEcCtD
Regorafenib—Headache—Ethinyl Estradiol—osteoporosis	0.000216	0.00108	CcSEcCtD
Regorafenib—Vomiting—Risedronate—osteoporosis	0.000214	0.00107	CcSEcCtD
Regorafenib—Rash—Risedronate—osteoporosis	0.000212	0.00106	CcSEcCtD
Regorafenib—Dermatitis—Risedronate—osteoporosis	0.000212	0.00106	CcSEcCtD
Regorafenib—Headache—Risedronate—osteoporosis	0.000211	0.00106	CcSEcCtD
Regorafenib—Asthenia—Zoledronate—osteoporosis	0.00021	0.00105	CcSEcCtD
Regorafenib—Nausea—Ethinyl Estradiol—osteoporosis	0.000205	0.00103	CcSEcCtD
Regorafenib—Vomiting—Pamidronate—osteoporosis	0.000203	0.00102	CcSEcCtD
Regorafenib—Asthenia—Conjugated Estrogens—osteoporosis	0.000202	0.00101	CcSEcCtD
Regorafenib—Rash—Pamidronate—osteoporosis	0.000202	0.00101	CcSEcCtD
Regorafenib—Dermatitis—Pamidronate—osteoporosis	0.000201	0.00101	CcSEcCtD
Regorafenib—Headache—Pamidronate—osteoporosis	0.0002	0.00101	CcSEcCtD
Regorafenib—Diarrhoea—Zoledronate—osteoporosis	0.0002	0.001	CcSEcCtD
Regorafenib—Nausea—Risedronate—osteoporosis	0.0002	0.001	CcSEcCtD
Regorafenib—ABCB1—uterus—osteoporosis	0.000198	0.00591	CbGeAlD
Regorafenib—Decreased appetite—Estradiol—osteoporosis	0.000196	0.000982	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000194	0.000975	CcSEcCtD
Regorafenib—Fatigue—Estradiol—osteoporosis	0.000194	0.000974	CcSEcCtD
Regorafenib—Pain—Estradiol—osteoporosis	0.000193	0.000966	CcSEcCtD
Regorafenib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000192	0.000966	CcSEcCtD
Regorafenib—Nausea—Pamidronate—osteoporosis	0.00019	0.000953	CcSEcCtD
Regorafenib—Vomiting—Zoledronate—osteoporosis	0.000186	0.000932	CcSEcCtD
Regorafenib—Rash—Zoledronate—osteoporosis	0.000184	0.000924	CcSEcCtD
Regorafenib—Gastrointestinal pain—Estradiol—osteoporosis	0.000184	0.000924	CcSEcCtD
Regorafenib—Dermatitis—Zoledronate—osteoporosis	0.000184	0.000923	CcSEcCtD
Regorafenib—Headache—Zoledronate—osteoporosis	0.000183	0.000918	CcSEcCtD
Regorafenib—Vomiting—Conjugated Estrogens—osteoporosis	0.000179	0.000897	CcSEcCtD
Regorafenib—Abdominal pain—Estradiol—osteoporosis	0.000178	0.000893	CcSEcCtD
Regorafenib—Body temperature increased—Estradiol—osteoporosis	0.000178	0.000893	CcSEcCtD
Regorafenib—Rash—Conjugated Estrogens—osteoporosis	0.000177	0.00089	CcSEcCtD
Regorafenib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000177	0.000889	CcSEcCtD
Regorafenib—Headache—Conjugated Estrogens—osteoporosis	0.000176	0.000884	CcSEcCtD
Regorafenib—Nausea—Zoledronate—osteoporosis	0.000174	0.000871	CcSEcCtD
Regorafenib—ABCB1—bone marrow—osteoporosis	0.000168	0.00501	CbGeAlD
Regorafenib—Nausea—Conjugated Estrogens—osteoporosis	0.000167	0.000838	CcSEcCtD
Regorafenib—Asthenia—Estradiol—osteoporosis	0.000162	0.00081	CcSEcCtD
Regorafenib—Diarrhoea—Estradiol—osteoporosis	0.000154	0.000773	CcSEcCtD
Regorafenib—Vomiting—Estradiol—osteoporosis	0.000143	0.000718	CcSEcCtD
Regorafenib—Rash—Estradiol—osteoporosis	0.000142	0.000712	CcSEcCtD
Regorafenib—Dermatitis—Estradiol—osteoporosis	0.000142	0.000712	CcSEcCtD
Regorafenib—Headache—Estradiol—osteoporosis	0.000141	0.000708	CcSEcCtD
Regorafenib—Nausea—Estradiol—osteoporosis	0.000134	0.000671	CcSEcCtD
Regorafenib—PDGFRA—Signaling Pathways—ADCY5—osteoporosis	8.15e-06	3.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—POMC—osteoporosis	8.15e-06	3.5e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6R—osteoporosis	8.15e-06	3.5e-05	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—IL6—osteoporosis	8.11e-06	3.48e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—LEP—osteoporosis	8.1e-06	3.47e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL1B—osteoporosis	8.06e-06	3.46e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ADCY5—osteoporosis	8.05e-06	3.45e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ADCY5—osteoporosis	8.05e-06	3.45e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP27A1—osteoporosis	8.04e-06	3.45e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—RAP1A—osteoporosis	8.03e-06	3.44e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—GPX1—osteoporosis	8.02e-06	3.44e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—GPX1—osteoporosis	8.02e-06	3.44e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IRS1—osteoporosis	8.01e-06	3.44e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ATIC—osteoporosis	8e-06	3.43e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PNP—osteoporosis	8e-06	3.43e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TPI1—osteoporosis	7.97e-06	3.42e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6R—osteoporosis	7.97e-06	3.42e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6R—osteoporosis	7.95e-06	3.41e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6R—osteoporosis	7.94e-06	3.41e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SPP1—osteoporosis	7.91e-06	3.39e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SPP1—osteoporosis	7.89e-06	3.38e-05	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	7.88e-06	3.38e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	7.86e-06	3.37e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IGF1—osteoporosis	7.86e-06	3.37e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—IL6—osteoporosis	7.86e-06	3.37e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ACP5—osteoporosis	7.82e-06	3.35e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—ESR1—osteoporosis	7.81e-06	3.35e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—osteoporosis	7.8e-06	3.34e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TPI1—osteoporosis	7.78e-06	3.34e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—ESR1—osteoporosis	7.73e-06	3.32e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IRS1—osteoporosis	7.73e-06	3.32e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.72e-06	3.31e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IRS2—osteoporosis	7.67e-06	3.29e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ENO1—osteoporosis	7.66e-06	3.29e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PSMA2—osteoporosis	7.55e-06	3.24e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PSMA5—osteoporosis	7.55e-06	3.24e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IRS2—osteoporosis	7.54e-06	3.23e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6R—osteoporosis	7.53e-06	3.23e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—LEP—osteoporosis	7.51e-06	3.22e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—P4HB—osteoporosis	7.49e-06	3.21e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—IL6—osteoporosis	7.44e-06	3.19e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL1B—osteoporosis	7.4e-06	3.18e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—MTHFR—osteoporosis	7.4e-06	3.17e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—MTHFR—osteoporosis	7.4e-06	3.17e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—LEP—osteoporosis	7.37e-06	3.16e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GAPDH—osteoporosis	7.36e-06	3.15e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ADCY5—osteoporosis	7.34e-06	3.15e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—P4HB—osteoporosis	7.31e-06	3.14e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—IL6—osteoporosis	7.31e-06	3.14e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IRS1—osteoporosis	7.3e-06	3.13e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL1B—osteoporosis	7.27e-06	3.12e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TPI1—osteoporosis	7.27e-06	3.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6R—osteoporosis	7.27e-06	3.12e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IRS1—osteoporosis	7.23e-06	3.1e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GAPDH—osteoporosis	7.18e-06	3.08e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—ESR1—osteoporosis	7.17e-06	3.07e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—RAP1A—osteoporosis	7.16e-06	3.07e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL6—osteoporosis	7.15e-06	3.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IRS2—osteoporosis	7.15e-06	3.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IRS1—osteoporosis	7.14e-06	3.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IRS2—osteoporosis	7.13e-06	3.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SPP1—osteoporosis	7.11e-06	3.05e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MYC—osteoporosis	7.1e-06	3.04e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TGFB1—osteoporosis	7.08e-06	3.04e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—ESR1—osteoporosis	7.04e-06	3.02e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—POMC—osteoporosis	7.03e-06	3.01e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	7e-06	3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—LEP—osteoporosis	7e-06	3e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—RAP1A—osteoporosis	6.99e-06	3e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—LEP—osteoporosis	6.98e-06	2.99e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—POMC—osteoporosis	6.96e-06	2.98e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—osteoporosis	6.94e-06	2.98e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—osteoporosis	6.92e-06	2.97e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1B—osteoporosis	6.9e-06	2.96e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1B—osteoporosis	6.88e-06	2.95e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—osteoporosis	6.88e-06	2.95e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6R—osteoporosis	6.85e-06	2.94e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—P4HB—osteoporosis	6.83e-06	2.93e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ADCY5—osteoporosis	6.83e-06	2.93e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GPX1—osteoporosis	6.81e-06	2.92e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CA2—osteoporosis	6.8e-06	2.92e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—OXCT1—osteoporosis	6.8e-06	2.92e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6R—osteoporosis	6.79e-06	2.91e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IGF1—osteoporosis	6.76e-06	2.9e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6R—osteoporosis	6.71e-06	2.88e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GAPDH—osteoporosis	6.71e-06	2.88e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IRS1—osteoporosis	6.7e-06	2.87e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IGF1—osteoporosis	6.69e-06	2.87e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ESR1—osteoporosis	6.68e-06	2.87e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ESR1—osteoporosis	6.66e-06	2.86e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MGLL—osteoporosis	6.63e-06	2.84e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IRS1—osteoporosis	6.58e-06	2.82e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ADCY5—osteoporosis	6.55e-06	2.81e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—RAP1A—osteoporosis	6.53e-06	2.8e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ENO1—osteoporosis	6.49e-06	2.78e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—POMC—osteoporosis	6.45e-06	2.77e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IRS2—osteoporosis	6.43e-06	2.76e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PSMA5—osteoporosis	6.39e-06	2.74e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PSMA2—osteoporosis	6.39e-06	2.74e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—POMC—osteoporosis	6.34e-06	2.72e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SPP1—osteoporosis	6.33e-06	2.72e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6R—osteoporosis	6.29e-06	2.7e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—osteoporosis	6.29e-06	2.7e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—LEP—osteoporosis	6.29e-06	2.7e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—MTHFR—osteoporosis	6.28e-06	2.69e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.25e-06	2.68e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—MYC—osteoporosis	6.25e-06	2.68e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IRS1—osteoporosis	6.24e-06	2.68e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—osteoporosis	6.23e-06	2.67e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IRS1—osteoporosis	6.23e-06	2.67e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IGF1—osteoporosis	6.2e-06	2.66e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1B—osteoporosis	6.2e-06	2.66e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6R—osteoporosis	6.18e-06	2.65e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CYP19A1—osteoporosis	6.13e-06	2.63e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IGF1—osteoporosis	6.09e-06	2.61e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—osteoporosis	6.08e-06	2.61e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1B—osteoporosis	6.04e-06	2.59e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—POMC—osteoporosis	6.01e-06	2.58e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ESR1—osteoporosis	6e-06	2.57e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—POMC—osteoporosis	6e-06	2.57e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—POMC—osteoporosis	5.92e-06	2.54e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—POMC—osteoporosis	5.92e-06	2.54e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6R—osteoporosis	5.86e-06	2.52e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6R—osteoporosis	5.85e-06	2.51e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ENO1—osteoporosis	5.79e-06	2.48e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IGF1—osteoporosis	5.78e-06	2.48e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IGF1—osteoporosis	5.77e-06	2.47e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MYC—osteoporosis	5.75e-06	2.46e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—TGFB1—osteoporosis	5.73e-06	2.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IRS2—osteoporosis	5.73e-06	2.46e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PSMA2—osteoporosis	5.71e-06	2.45e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PSMA5—osteoporosis	5.71e-06	2.45e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.7e-06	2.44e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ENO1—osteoporosis	5.65e-06	2.42e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—IDH2—osteoporosis	5.64e-06	2.42e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IRS1—osteoporosis	5.61e-06	2.41e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—LEP—osteoporosis	5.61e-06	2.4e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PSMA2—osteoporosis	5.57e-06	2.39e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PSMA5—osteoporosis	5.57e-06	2.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—osteoporosis	5.56e-06	2.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1B—osteoporosis	5.53e-06	2.37e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—POMC—osteoporosis	5.4e-06	2.32e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ESR1—osteoporosis	5.35e-06	2.3e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—osteoporosis	5.34e-06	2.29e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MYC—osteoporosis	5.32e-06	2.28e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—TGFB1—osteoporosis	5.31e-06	2.28e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP27A1—osteoporosis	5.3e-06	2.27e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ENO1—osteoporosis	5.28e-06	2.26e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6R—osteoporosis	5.27e-06	2.26e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MYC—osteoporosis	5.23e-06	2.24e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—TGFB1—osteoporosis	5.22e-06	2.24e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PSMA2—osteoporosis	5.2e-06	2.23e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PSMA5—osteoporosis	5.2e-06	2.23e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IGF1—osteoporosis	5.2e-06	2.23e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP19A1—osteoporosis	5.19e-06	2.22e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ACP5—osteoporosis	5.16e-06	2.21e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—POMC—osteoporosis	5.02e-06	2.15e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ADCY5—osteoporosis	5.01e-06	2.15e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IRS1—osteoporosis	5e-06	2.14e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MYC—osteoporosis	5e-06	2.14e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GPX1—osteoporosis	4.99e-06	2.14e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TGFB1—osteoporosis	4.99e-06	2.14e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MYC—osteoporosis	4.96e-06	2.13e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—TGFB1—osteoporosis	4.95e-06	2.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MYC—osteoporosis	4.95e-06	2.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—TGFB1—osteoporosis	4.94e-06	2.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—POMC—osteoporosis	4.82e-06	2.07e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TPI1—osteoporosis	4.79e-06	2.06e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MYC—osteoporosis	4.72e-06	2.03e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—osteoporosis	4.72e-06	2.03e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TGFB1—osteoporosis	4.71e-06	2.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6R—osteoporosis	4.7e-06	2.01e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF1—osteoporosis	4.63e-06	1.99e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP19A1—osteoporosis	4.63e-06	1.99e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—MTHFR—osteoporosis	4.6e-06	1.97e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP19A1—osteoporosis	4.52e-06	1.94e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—P4HB—osteoporosis	4.51e-06	1.93e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MYC—osteoporosis	4.46e-06	1.91e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TGFB1—osteoporosis	4.45e-06	1.91e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GAPDH—osteoporosis	4.42e-06	1.9e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—osteoporosis	4.34e-06	1.86e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—osteoporosis	4.32e-06	1.85e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—RAP1A—osteoporosis	4.31e-06	1.85e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—osteoporosis	4.26e-06	1.83e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ADCY5—osteoporosis	4.24e-06	1.82e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GPX1—osteoporosis	4.22e-06	1.81e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP19A1—osteoporosis	4.22e-06	1.81e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—osteoporosis	4.06e-06	1.74e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TGFB1—osteoporosis	4.05e-06	1.74e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—osteoporosis	4.04e-06	1.73e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—osteoporosis	4.03e-06	1.73e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—osteoporosis	4.02e-06	1.73e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TGFB1—osteoporosis	4.01e-06	1.72e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—osteoporosis	4e-06	1.72e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—osteoporosis	3.97e-06	1.7e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFB1—osteoporosis	3.97e-06	1.7e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—osteoporosis	3.93e-06	1.69e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—osteoporosis	3.9e-06	1.67e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ADCY5—osteoporosis	3.78e-06	1.62e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GPX1—osteoporosis	3.77e-06	1.62e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—osteoporosis	3.76e-06	1.61e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—osteoporosis	3.73e-06	1.6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—osteoporosis	3.73e-06	1.6e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—osteoporosis	3.72e-06	1.6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—osteoporosis	3.72e-06	1.6e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ADCY5—osteoporosis	3.69e-06	1.58e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—POMC—osteoporosis	3.68e-06	1.58e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GPX1—osteoporosis	3.68e-06	1.58e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—osteoporosis	3.66e-06	1.57e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—osteoporosis	3.65e-06	1.57e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—osteoporosis	3.63e-06	1.56e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—osteoporosis	3.55e-06	1.52e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—osteoporosis	3.54e-06	1.52e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—osteoporosis	3.54e-06	1.52e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO1—osteoporosis	3.48e-06	1.49e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—osteoporosis	3.48e-06	1.49e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—osteoporosis	3.48e-06	1.49e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—osteoporosis	3.47e-06	1.49e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—osteoporosis	3.47e-06	1.49e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—osteoporosis	3.46e-06	1.48e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ADCY5—osteoporosis	3.45e-06	1.48e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GPX1—osteoporosis	3.44e-06	1.47e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PSMA2—osteoporosis	3.43e-06	1.47e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PSMA5—osteoporosis	3.43e-06	1.47e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—osteoporosis	3.4e-06	1.46e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—osteoporosis	3.35e-06	1.44e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—osteoporosis	3.24e-06	1.39e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—osteoporosis	3.17e-06	1.36e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—osteoporosis	3.12e-06	1.34e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—POMC—osteoporosis	3.12e-06	1.34e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—osteoporosis	3.12e-06	1.34e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—osteoporosis	3.05e-06	1.31e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—osteoporosis	3.02e-06	1.3e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—osteoporosis	2.99e-06	1.28e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—osteoporosis	2.8e-06	1.2e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.78e-06	1.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—osteoporosis	2.78e-06	1.19e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—POMC—osteoporosis	2.78e-06	1.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—osteoporosis	2.78e-06	1.19e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—osteoporosis	2.75e-06	1.18e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—POMC—osteoporosis	2.72e-06	1.16e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—osteoporosis	2.61e-06	1.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—osteoporosis	2.61e-06	1.12e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—POMC—osteoporosis	2.54e-06	1.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—osteoporosis	2.35e-06	1.01e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ADCY5—osteoporosis	2.27e-06	9.76e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GPX1—osteoporosis	2.27e-06	9.72e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—osteoporosis	2.09e-06	8.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—osteoporosis	2.09e-06	8.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—POMC—osteoporosis	1.67e-06	7.18e-06	CbGpPWpGaD
